Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:PSDV's Cash to Debt is ranked higher than
99% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NAS:PSDV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:PSDV' s Cash to Debt Range Over the Past 10 Years
Min: 0.47  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.58
NAS:PSDV's Equity to Asset is ranked lower than
57% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:PSDV: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NAS:PSDV' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.69 Max: 0.91
Current: 0.58
0.47
0.91
Interest Coverage No Debt
NAS:PSDV's Interest Coverage is ranked higher than
99% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. NAS:PSDV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:PSDV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -15.48
M-Score: -4.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1675.47
NAS:PSDV's Operating margin (%) is ranked lower than
95% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. NAS:PSDV: -1675.47 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:PSDV' s Operating margin (%) Range Over the Past 10 Years
Min: -2445.54  Med: -474.92 Max: 39.44
Current: -1675.47
-2445.54
39.44
Net-margin (%) -1661.50
NAS:PSDV's Net-margin (%) is ranked lower than
95% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:PSDV: -1661.50 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:PSDV' s Net-margin (%) Range Over the Past 10 Years
Min: -4638.7  Med: -469.92 Max: 37.97
Current: -1661.5
-4638.7
37.97
ROE (%) -124.97
NAS:PSDV's ROE (%) is ranked lower than
94% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. NAS:PSDV: -124.97 )
Ranked among companies with meaningful ROE (%) only.
NAS:PSDV' s ROE (%) Range Over the Past 10 Years
Min: -133.19  Med: -97.19 Max: 33.15
Current: -124.97
-133.19
33.15
ROA (%) -82.48
NAS:PSDV's ROA (%) is ranked lower than
94% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NAS:PSDV: -82.48 )
Ranked among companies with meaningful ROA (%) only.
NAS:PSDV' s ROA (%) Range Over the Past 10 Years
Min: -95.61  Med: -65.97 Max: 23.06
Current: -82.48
-95.61
23.06
ROC (Joel Greenblatt) (%) -8061.87
NAS:PSDV's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. NAS:PSDV: -8061.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:PSDV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -15359.59  Med: -6301.23 Max: 16680.73
Current: -8061.87
-15359.59
16680.73
Revenue Growth (3Y)(%) -18.10
NAS:PSDV's Revenue Growth (3Y)(%) is ranked lower than
88% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NAS:PSDV: -18.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:PSDV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.8 Max: 365.7
Current: -18.1
0
365.7
EBITDA Growth (3Y)(%) 11.30
NAS:PSDV's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. NAS:PSDV: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:PSDV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 933.8
Current: 11.3
0
933.8
EPS Growth (3Y)(%) 9.40
NAS:PSDV's EPS Growth (3Y)(%) is ranked higher than
55% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:PSDV: 9.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:PSDV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.05 Max: 348.3
Current: 9.4
0
348.3
» NAS:PSDV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PSDV Guru Trades in Q4 2015

Jim Simons 595,800 sh (+37.02%)
Ken Fisher 12,057 sh (unchged)
» More
Q1 2016

PSDV Guru Trades in Q1 2016

Ken Fisher 12,057 sh (unchged)
Jim Simons 574,800 sh (-3.52%)
» More
Q2 2016

PSDV Guru Trades in Q2 2016

Jim Simons 586,900 sh (+2.11%)
Ken Fisher 12,057 sh (unchged)
» More
Q3 2016

PSDV Guru Trades in Q3 2016

Jim Simons 677,100 sh (+15.37%)
Ken Fisher 12,057 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:ADMP, NAS:LPCN, NAS:JNP, NAS:MEIP, NAS:STDY, NAS:EPIX, NAS:CPHR, OTCPK:NRIFF, OTCPK:MRPHF, NAS:ARDM, NAS:FCSC, NAS:SPHS, NAS:SCYX, NAS:CPIX, NAS:IMMY, OTCPK:BKIT, NAS:OREX, OTCPK:SPLIF, OTCPK:GLDFF, NAS:PTX » details
Traded in other countries:PVA.Australia, PV3.Germany, PSIZF.USA,
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.

pSivida Corp was organized as a Delaware Corporation in March 2008. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is engaged in the treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials and uses different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal and marketing authorization is pending in Italy and Spain. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. Its competitors and potential competitors are larger, established and more experienced and have more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.

Top Ranked Articles about pSivida Corp

Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Insiders at 4 companies sell their stock
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Read more...

Ratios

vs
industry
vs
history
P/B 4.20
PSDV's P/B is ranked lower than
70% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. PSDV: 4.20 )
Ranked among companies with meaningful P/B only.
PSDV' s P/B Range Over the Past 10 Years
Min: 0.01  Med: 2.81 Max: 11.73
Current: 4.2
0.01
11.73
P/S 38.68
PSDV's P/S is ranked lower than
93% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. PSDV: 38.68 )
Ranked among companies with meaningful P/S only.
PSDV' s P/S Range Over the Past 10 Years
Min: 0.38  Med: 11.36 Max: 131.06
Current: 38.68
0.38
131.06
Current Ratio 4.85
PSDV's Current Ratio is ranked higher than
78% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. PSDV: 4.85 )
Ranked among companies with meaningful Current Ratio only.
PSDV' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.63 Max: 17.6
Current: 4.85
0.26
17.6
Quick Ratio 4.85
PSDV's Quick Ratio is ranked higher than
81% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. PSDV: 4.85 )
Ranked among companies with meaningful Quick Ratio only.
PSDV' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.63 Max: 17.6
Current: 4.85
0.26
17.6
Days Sales Outstanding 117.84
PSDV's Days Sales Outstanding is ranked lower than
77% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. PSDV: 117.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
PSDV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.55  Med: 81.04 Max: 493.85
Current: 117.84
8.55
493.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
PSDV's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. PSDV: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PSDV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -467.6  Med: -7.9 Max: 0
Current: -13.6
-467.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.97
PSDV's Price/Net Cash is ranked higher than
73% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. PSDV: 4.97 )
Ranked among companies with meaningful Price/Net Cash only.
PSDV' s Price/Net Cash Range Over the Past 10 Years
Min: 0.45  Med: 6.85 Max: 223.64
Current: 4.97
0.45
223.64
Price/Net Current Asset Value 4.58
PSDV's Price/Net Current Asset Value is ranked higher than
69% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.66 vs. PSDV: 4.58 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PSDV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.16  Med: 5.68 Max: 94.62
Current: 4.58
0.16
94.62
Price/Tangible Book 4.35
PSDV's Price/Tangible Book is ranked lower than
60% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. PSDV: 4.35 )
Ranked among companies with meaningful Price/Tangible Book only.
PSDV' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.15  Med: 5.59 Max: 33.47
Current: 4.35
0.15
33.47
Price/Median PS Value 3.35
PSDV's Price/Median PS Value is ranked lower than
92% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. PSDV: 3.35 )
Ranked among companies with meaningful Price/Median PS Value only.
PSDV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 1.21 Max: 906.67
Current: 3.35
0.07
906.67
Earnings Yield (Greenblatt) (%) -62.74
PSDV's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. PSDV: -62.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PSDV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -65.68  Med: 7.3 Max: 20.6
Current: -62.74
-65.68
20.6

More Statistics

Revenue (TTM) (Mil) $1.43
EPS (TTM) $ -0.73
Beta1.97
Short Percentage of Float1.79%
52-Week Range $1.65 - 5.81
Shares Outstanding (Mil)34.18
» More Articles for PSDV

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 

More From Other Websites
ETFs with exposure to pSivida Corp. : December 2, 2016 Dec 02 2016
PSIVIDA CORP. Financials Nov 17 2016
ETF’s with exposure to pSivida Corp. : November 10, 2016 Nov 10 2016
pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016 Nov 09 2016
PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Nov 08 2016
Edited Transcript of PSDV earnings conference call or presentation 7-Nov-16 9:30pm GMT Nov 07 2016
PSivida reports 1Q loss Nov 07 2016
PSivida reports 1Q loss Nov 07 2016
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives... Nov 07 2016
Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial... Nov 07 2016
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 07 2016
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives... Nov 07 2016
Q1 2017 pSivida Corp Earnings Release - After Market Close Nov 07 2016
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference... Oct 31 2016
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference... Oct 31 2016
ETF’s with exposure to pSivida Corp. : October 28, 2016 Oct 28 2016
ETF’s with exposure to pSivida Corp. : October 18, 2016 Oct 18 2016
pSivida Corp. :PSDV-US: Earnings Analysis: 2016 By the Numbers : October 17, 2016 Oct 17 2016
Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target Oct 04 2016
Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target Oct 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)